Abstracts tagged "Biologic agents"

Abstract Number: 2319 • 2013 ACR/ARHP Annual Meeting
Comparative Safety Of Biological Agents Among Medicare Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸, Paul M. Muntner¹ and Jeffrey R. Curtis³, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several new biologic disease-modifying antirheumatic drugs (DMARDs) have been approved for treatment of rheumatoid arthritis (RA) in United States. However, their comparative risks of…
Abstract Number: 1468 • 2013 ACR/ARHP Annual Meeting
Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Martin J. Bergman², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Kristin King⁴, Jae Oh⁴, Monarch Shah¹ and Max I. Hamburger⁵, ¹ICON Clinical Research, San Francisco, CA, ²Taylor Hospital, Ridley Park, PA, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Rheumatology Associates, Melville, NY
Background/Purpose: Results from randomized controlled trials indicate that about one-third of rheumatoid arthritis (RA) patients initially treated with anti-TNF agents do not respond, show a…
Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Zaki AbouZahr¹, Andrew Spiegelman², Maria Cantu³ and Bernard Ng⁴, ¹Baylor College of Medicine, Houston, TX, ²Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, ³Baylor College Of Medicine, Houston, TX, ⁴Michael E. DeBakey VA Medical Center, Houston, TX
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
Abstract Number: 2326 • 2013 ACR/ARHP Annual Meeting
Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
Michael E. Weinblatt¹, Michael H Schiff², Robert Valente³, Désirée M. van der Heijde⁴, Gustavo Citera⁵, Ayanbola Elegbe⁶, Michael A Maldonado⁶ and Roy Fleischmann⁷, ¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Denver, CO, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) is the first 2 year, active comparator study in RA patients utilizing…
Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Arthur N. Lau¹, Alpesh Shah², Melissa Deamude³, Cynthia Mech⁴, Robert Bensen⁵ and William G. Bensen⁶, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…
Abstract Number: 481 • 2013 ACR/ARHP Annual Meeting
Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice
Miguel Arredondo¹, Iciar Cañamares², Esther Ramírez-Herráiz², Isidoro Gonzalez-Alvaro³, Alberto Garcia-Vadillo³, Alberto Morell¹, Rosario Garcia-Vicuña⁴ and Jose María Alvaro-Gracia⁵, ¹Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Servicio de Farmacia, Hospital Universitario de La Princesa, Madrid, Spain, ³Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁵Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: One of the limiting factors for the use of biological therapies (BT) is cost. For this reason, the development of cost optimization strategies without…
Abstract Number: 2208 • 2013 ACR/ARHP Annual Meeting
Psychological Condition Of JIA Patients Treated With Biologic Agents. – A Nation-Wide Survey In Japan
Yuki Osako¹, Yukiko Nonaka², Harumi Akaike², Tomohiro Kubota³, Tsuyoshi Yamatou², Tomokazu Nagakura⁴, Junko Yasumura⁵, Hiroyuki Imanaka² and Syuji Takei⁶, ¹School of Health Sciences, Faculty of Medicine,Department of Maternal & Child Nursing and Midwifery, Kagoshima University, Kagoshima city, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Biologic agents, newly developed medications targeting for inflammatory cytokines such as TNF-alpha or IL-6, have been drastically improving the disease course of JIA who…
Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis
Charles Inderjeeth¹, Andrew Redfern¹, Michael Huang², Yun Hardiman², Theresa Grant², Lawrence C. Fritz², David Fuller³, David Haughey⁴ and Mark C. Totoritis², ¹Linear Clinical Research Ltd, Perth, Australia, ²Santarus, Inc., San Diego, CA, ³INC Research, Inc., New South Wales, Australia, ⁴ICON Development Solutions, Whitesboro, NY
Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…
Abstract Number: 484 • 2013 ACR/ARHP Annual Meeting
Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Max I. Hamburger², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Jae Oh⁴, Kristin King⁴, Monarch Shah¹ and Martin J. Bergman⁵, ¹ICON Clinical Research, San Francisco, CA, ²Rheumatology Associates, Melville, NY, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Taylor Hospital, Ridley Park, PA
Background/Purpose: Rheumatoid arthritis (RA) patients who have failed an anti-TNF agent as their first biologic agent have the option of switching to a second aTNF…
Abstract Number: 2165 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Patients With Poly-Articular Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Controlled Withdrawal Trials
Gil Amarilyo¹, Simon Tarp², Ivan Foeldvari³, Neta Cohen⁴, Tracy D. Pope⁵, Jennifer M.P. Woo⁶, Robin Christensen² and Daniel Furst⁵, ¹Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁴Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA, ⁶Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Although various biologic agents (BAs) are in use for polyarticular juvenile idiopathic arthritis (pJIA), a combined meta-analytic summary comparing the efficacy and safety among…
Abstract Number: 1444 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Sonia Cabrera¹, Virginia Ruiz-Esquide³, Julio Ramirez¹, Juan D. Cañete², Jordi Yague⁴ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain, ⁴Hospital Clínic / IDIBAPS, Barcelona, Spain
Background/Purpose: Biological therapy has proved efficacious in various chronic inflammatory arthropathies but, in practice, clinical efficacy is reduced in some patients, suggesting drug-induced immunogenicity as…
Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Vance J. Bray¹, Adam W. Bagley², Sterling G. West³, Carol J. Etzel⁴, Joel M. Kremer⁵ and Jason R. Kolfenbach⁶, ¹Denver Arthritis Clinic, Denver, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, UT MD Anderson, Houston, TX, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…
Abstract Number: L10 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients with Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation of Etanercept 50 Mg Weekly or 25 Mg Weekly Are Both Clinically Superior to Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
R.F. van Vollenhoven¹, Mikkel Østergaard², Marjatta Leirisalo-Repo³, Till Uhlig⁴, Marita Jansson⁵, Åsa Klackenberg⁵, Katherine Hutchinson⁶ and Karin Franck-Larsson⁵, ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Speciality Care Nordic Medical Affairs, Pfizer Nordic, Sollentuna, Sweden, ⁶Quanticate, Hitchin, United Kingdom
Background/Purpose: The efficacy of etanercept (ETN) in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) is well established, and long-term trials1 and…
Abstract Number: L4 • 2012 ACR/ARHP Annual Meeting
Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Iain B. McInnes², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Mittie K. Doyle⁸ and Alan M. Mendelsohn⁹, ¹UCSD School of Medicine, La Jolla, CA, ²University of Glasgow, Glasgow, Scotland, ³Tufts Medical Center, Boston, MA, ⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: PSUMMIT I ,through wk24, demonstrated efficacy and safety of ustekinumab (UST) in reducing signs and symptoms of active psoriatic arthritis (PsA) in a large,…
Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Bruno Fautrel¹, Thao Pham², Florence Tubach³, Toni Alfaiate⁴, Jacques Morel⁵, Emmanuelle Dernis⁶, Xavier J. Puechal⁷, Philippe Gaudin⁸ and Xavier Mariette⁹, ¹Rheumatology, UPMC - Paris 6 University, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Centre Hospitalier, Le Mans, France, ⁷Le Mans Hospital, Le Mans, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…